Pertuzumab (anti-HER2)

製品コード：A2008         Batch: A200802

印刷

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.

製品説明

CAS No. 380610-27-5
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99.17%
Protein concentration 5.02mg/ml
Endotoxin Level ≤1 EU/mg

カスタマーフィードバック

A2008-Pertuzumab-(anti-HER2).gif

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Optical biosensor based on weak value amplification for the high sensitivity detection of Pertuzumab in combination with Trastuzumab binding to the extracellular domain of HER2 [ Optics Express, September 26, 2022, 36839-36848]
An approach to produce thousands of single-chain antibody variants on a SPR biosensor chip for measuring target binding kinetics and for deep characterization of antibody paratopes [ bioRxiv, January 14, 2025, 2025.01.11.632576] PubMed: 39868233
Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor [ Science Advances, February 6, 2026, eadu0690] PubMed: 41637511
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells [ Clinical Cancer Research, 2025, CCR-24-2449] PubMed: 40029253
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Anti-Tumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells [ Clin Cancer Res, 2025, 10.1158/1078-0432.CCR-24-2449] PubMed: 40029253
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy [ Antibodies (Basel), 2025, 14(1)21] PubMed: 40136470
Characterization of ex vivo expanded natural killer cells for cancer immunotherapy [ Immunol Cell Biol, 2025, 10.1111/imcb.70038] PubMed: 40533418
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy [ Antibodies, 2025, 21] PubMed: 40136470
Intracellular cartilage oligomeric matrix protein augments breast cancer resistance to chemotherapy [ Cell Death Dis, 2024, 15(7):480] PubMed: 38965233
Trastuzumab Potentiates Antitumor Activity of Thiopyrano[2,3-d]Thiazole Derivative in AGS Gastric Cancer Cells [ Molecules, 2024, 29(21)5117] PubMed: 39519758

人間や獣医の診断であるか治療的な使用のためにでない。